ATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMAS
Sahebjam S, Forsyth P, Tran N, Etame A, Arrington J, Jaglal M, Mokhtari S, MacAulay R, Wicklund M, Evernden B, Gatewood T, Robinson T, Raval R, Yu M. ATIM-17. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) COMBINED WITH NIVOLUMAB (NIVO), IPILIMUMAB (IPI) AND BEVACIZUMAB (BEV) IN PATIENTS (PTS) WITH RECURRENT HIGH GRADE GLIOMAS. Neuro-Oncology 2019, 21: vi5-vi5. PMCID: PMC6847102, DOI: 10.1093/neuonc/noz175.017.Peer-Reviewed Original ResearchGrade 1 elevationExpansion cohortSafety cohortPD-1/PDLStrong pre-clinical evidencesAnti-tumor immune responseRecurrent high-grade gliomaPhase IDose-expansion cohortsGrade 1 anorexiaGrade 1 diarrheaRT treatment fieldUse of corticosteroidsPre-clinical evidenceHigh-grade gliomasPrimary study objectiveCommon toxicitiesEligible ptsPrior RTSecondary endpointsFlat doseRecurrent tumorsGrade IIITumor regressionEfficacy data